Search results
356 Results for 'Donald E. Ingber'
- Technologies (36)
- Collaborations (3)
- Team (0)
- News (238)
- Pages (0)
- Multimedia (61)
- Publications (0)
- Jobs (0)
- Events (18)
Technologies 36
-
ENDOx: Reimagining Endometriosis Care Through Precision Nanomedicine
Endometriosis is characterized by the abnormal growth of tissue resembling the endometrium outside the uterus. It is estimated to affect 10–15% of reproductive-aged women and is associated with significant morbidity, including chronic pelvic pain and infertility. With no curative treatments currently available, standard therapies rely on hormonal suppression or invasive surgery, both of which are... -
COPDx: Rapid diagnostic to triage acute exacerbations
A point-of-care test based on new biomarkers to rapidly identify COPD patients who are high risk of acute exacerbations (AEs), determine the cause, and guide treatment. -
Blood Clot Dx
An ultra-sensitive triage test that identifies patients at risk for blood clots before they happen, enabling proactive treatment to reduce complications and deaths across a wide range of conditions. -
AminoX: Making Better Protein Drugs, Quicker and Cheaper
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition. -
Ichor: Reversing Aging
Ichor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health. -
NodeTX: Growing Lymph Nodes to Treat Cancer
NodeTX is a novel immunotherapy that leverages the human body's innate ability to grow lymph nodes to fight tumors.
Collaborations 3
-
Brain Shuttle Research Sponsorship & Licensing
Enabling brain-targeted drug development through non-exclusive licensing and pre-competitive research sponsorship. -
Kraft Heinz Partnership
The Kraft Heinz company approached the Wyss Institute for help to achieve its ambitious goal to make its food products healthier, resulting in a novel technology that is ripe for commercialization. -
Wyss Brain Targeting Program
Advancing brain delivery approaches that enable more safe and effective brain-targeted therapeutics.
News 238
Multimedia 61
-
Video/AnimationCutting to the Case: Don IngberDon Ingber, M.D., Ph.D., is the Founding Director of Harvard University’s Wyss Institute for Biologically Inspired Engineering and a pioneer of organ-on-a-chip technology. In this episode of Cutting to the Case, Ingber and host Cameron Sabet discuss how he helped create organs-on-chips, what these systems can teach us that traditional models cannot, and how biologically... -
Audio/PodcastBuying time: A medical breakthrough in stroke treatmentWhen a stroke strikes, every minute matters. Science has traditionally approached stroke as a race against time. But rather than racing faster, what if we could instead slow the damage down? Join host Shahni Wellington as she explores groundbreaking research aimed at buying more time for stroke patients, particularly those in rural and regional communities.... -
Audio/PodcastNext-Gen Toxicology: Inside the Organ Chip Revolution with Donald IngberIn this episode of ToxChats, hosts Lauren Walker and Sarah Benjamin sit down with the groundbreaking Donald Ingber—visionary scientist, engineer, and Founding Director of the Wyss Institute. Ingber shares how his unique path through medicine, biology, and design converged to spark breakthroughs such as human Organ Chips—systems that are redefining toxicology, drug development, and disease...
-
Video/Animation20-ish Questions with Donald E. Ingber20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows Donald E. Ingber, the Founding Director and a Core Faculty member at the Wyss Institute. He is also the Judah Folkman Professor of Vascular Biology at Harvard Medical... -
Audio/PodcastOrgans on Chips: Using Science, Art, and Design to Understand the Human Body – Talking About BloodIn this episode, Wyss Founding Director Don Ingber, M.D., Ph.D., talks with Helen Osborne about: How organ-on-chip and “human body on chips” technologies are built and how they realistically mimic human organ function by combining living cells, blood flow, and mechanical forces like breathing and stretch; The implications of these chips for hematology and clinical...
-
Audio/PodcastPlastic in our blood? That’s a problem. – Harvard ThinkingOur planet is filled with plastic. On average, we produce 430 million tons every year, most of which is used only for a short period of time and then discarded. But plastic isn’t just in the environment: it’s now in our bodies. Microplastics have been found in our bloodstreams, lungs, and other organs, and we’re...
Events 18
-
Jun 22, 2023, 11:00am - 12:00pmWebinar
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
Body-on-a-Chip technology is reshaping drug discovery, disease research, and personalized medicine. Please join a one-of-a-kind Ask Me Anything (AMA) session with the visionary behind it all: Donald Ingber. Prof. Ingber will be there, live, to answer YOUR questions and unveil the untapped potential of this groundbreaking technology. This is your chance to be part of... Free and open to public -
Mar 30, 2022, 1:00pm - 2:00pmWyss Event
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
Endothelial cells (ECs) are a heterogeneous and ductile cell type that serves as a critical interface between blood and diverse tissue microenvironments. ECs can adopt brain organotypic properties in response to their interaction a complex ecosystem of cells: adjacent mural smooth muscle cells and pericytes, perivascular immune cells, and surrounding astrocytes that differ across brain... Free and open to public -
Mar 3, 2021, 11:00am - 3:00pmLecture
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
Biologic drugs comprise 40 percent of the current drug development pipeline. Existing in vitro and animal models are limited in their ability to evaluate the safety and efficacy of these drugs in humans. These limitations often result in development delays and increased costs. Organs-on-chips emulate human biology by providing a micro-engineered environment lined with living... Free and open to public